AU2004245291A1

AU2004245291A1 - Improved production of rosuvastatin calcium salt

Info

Publication number: AU2004245291A1
Application number: AU2004245291A
Authority: AU
Inventors: Jeffrey Norman Crabb; John Horbury; Nigel Philip Taylor
Original assignee: AstraZeneca UK Ltd
Current assignee: AstraZeneca UK Ltd
Priority date: 2003-06-05
Filing date: 2004-06-03
Publication date: 2004-12-16
Anticipated expiration: 2024-06-03
Also published as: IS2751B; NZ543962A; NO332971B1; KR20060017848A; RU2005138370A; AR044773A1; BRPI0410922B1; TWI341310B; MXPA05013128A; AU2004245291B2; JP4651615B2; KR101099934B1; MY140820A; CA2527314A1; EP1633727A1; US8063213B2; NO20055730D0; JP2006526602A; GB0324793D0; WO2004108691A1

Description

WO 2004/108691 PCT/GB2004/002373 IMPROVED PRODUCTION OF ROSUVASTATIN CALCIUM SALT This invention concerns improvements to a chemical process, particularly a chemical process for manufacture of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 5 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt (1) (illustrated below), which is useful for the production of a pharmaceutical useful in the treatment of, inter alia, hypercholesterolemia, hyperlipoproteinemia and atherosclerosis. F OH OH 0 N COO- Ca 2 + , N -2 .0 1 The sodium salt (2) and calcium salt (1) of compound (E)-7-[4-(4-fluorophenyl)-6 isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6 enoic acid (hereinafter referred to as the 'Agent') were disclosed in European Patent 0521471. This patent also describes a process for the synthesis of the calcium salt (1), via the sodium 15 salt (2), as shown in Scheme 1 below. The calcium salt thus formed is then collected and dried and may be processed further as required.

WO 2004/108691 PCT/GB2004/002373 -2 F F O OH diethylmethoxyborane OH OH \ COOMe sodium borohydride 0I O N:; N COOMe j IN 'N I NaOH F F OH OH OH OH O N \ COO- Ca 2 + Calcium chloride \ COO / ' N 'N Na + 01 0I 12 Scheme 1 Our International Patent Application WO 00/49014 describes an alternative route to the calcium salt (1), also via the sodium salt (2), from the compound BEM (3), which is 5 exemplified as shown in Scheme 2 below: F F 3 2 S.NaCI, HI, 1. HC-5 deg C 2.methylamine water 2. NaOH S NOH OH CH)3 OH OH O / N cCa 2

ON\COO

"S )" N "AiNINjIO)-N lJ' " MeNH 3 + 1chmN 4 3 2m 1. NaCI, HCI, -5 deg C 2.methylamine .,water NaOH OH OH CaCI2r (aq) OH OH O N:; \ COO- Ca2+ \ COO 11N N MeNH+ 4 Scheme 2 WO 2004/108691 PCT/GB2004/002373 -3 As described in WO 00/49014, the transformation from BEM (3) to the calcium salt (1) may be carried out via the methylamine salt (4) as shown in Scheme 2. Isolation of this intermediate crystalline methylamine salt allows purification by recrystallisation before final formation of the (amorphous) calcium salt. 5 Our co-pending application WO 2004/014872 describes an improved process for isolation of the calcium salt from a water soluble salt, such as the transformation from the methylamine salt (4) to the calcium salt (1) in Scheme 2 above, wherein the improvement comprises adjustment of time and temperature parameters such that optimal physical form of the product is obtained. 10 We have surprisingly discovered an improvement to the process of manufacturing the calcium salt, which results in improved overall yield and a reduced number of steps to effect the transformation from BEM (3) to the calcium salt (1), whereby the step of isolating an intermediate salt is avoided. Surprisingly the quality of the resultant calcium salt product is not adversely affected. The process of this invention is also applicable to alkyl esters of the 15 agent other than the tertiary-butyl ester, BEM (3). According to the present invention there is provided an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a) to g): 20 a) reaction of a (1-6C)alkyl ester of (E)-(6- {2-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl I (4R,6S)-2,2-dimethyl[ 1,3]dioxan-4 yl)acetic acid in a water miscible organic solvent with aqueous acid at an elevated temperature; b) reaction of the resulting solution with an aqueous alkali metal hydroxide and 25 optionally washing the resulting aqueous alkali metal salt solution with a suitable organic solvent; c) adjustment of the pH of the resulting solution to between pH6 and pH1 1; d) removal of the water miscible organic solvent; e) optional filtration of the resulting mixture; 30 f) addition of a water soluble calcium salt to the filtrate so as to form (E)-7-[4-(4 fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5 dihydroxyhept-6-enoic acid calcium salt; and g) isolation of the product of step f).

WO 2004/108691 -4- PCT/GB2004/002373 It will be appreciated that this process achieves the conversion of the ester to the calcium salt (1) without isolation of an intermediate salt of the acid. Step a) 5 Suitable solvents for step a) are in general any water miscible organic solvent; for example solvents such as acetonitrile and acetone. A preferred solvent is acetonitrile. Suitable aqueous acids are acids whose calcium salt is water soluble so that it is not precipitated in Step f). In one embodiment, the aqueous acid is hydrochloric acid. In one aspect of this embodiment, the aqueous hydrochloric acid is approximately 0.1M. In another 10 aspect of this embodiment, the aqueous hydrochloric acid is <about 0.1M. Conveniently the aqueous hydrochloric acid is <0.05M, for example 0.02M. Suitably, the reaction of the (1-6C)alkyl ester of the Agent with aqueous acid is carried out between 30 and 50'C, conveniently between 35 and 40oC. More suitably, the (1-6C)alkylester of the Agent, dissolved in acetonitrile at 35 0 C is 15 reacted with aqueous hydrochloric acid at 35oC.. Suitable (1-6C)alkyl esters of the Agent are, for example methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl, pentyl or hexyl esters. BEM is a preferred example of a (1 6C)alkyl ester of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid. 20 The starting material BEM may be made as described in WO 00/49014. Analogues of BEM may be made by analogous processes, as illustrated in the Examples hereinafter. Step_ b) Step b) may be carried out at a temperature of between approximately 10 0 C and 25 approximately 40 0 C. Conveniently, step b) is carried out at ambient temperature, which will generally be understood to mean 20-25 0 C, conveniently approximately 25 0 C. Suitably the aqueous alkali metal hydroxide is aqueous potassium hydroxide or aqueous sodium hydroxide. In one embodiment, the aqueous alkali metal hydroxide is sodium hydroxide. In this 30 embodiment, suitably the aqueous sodium hydroxide is about 1M and sufficient quantity is added to form the sodium salt (2). It will be appreciated that the sodium salt (2) is not isolated and that the product of step b) is an aqueous sodium salt solution. It will also be appreciated that this aqueous sodium salt solution also contains acetonitrile.

WO 2004/108691 PCT/GB2004/002373 -5 The aqueous alkali metal salt solution may be washed with toluene, or another suitable organic solvent to remove unreacted (1-6C)alkyl ester of the Agent, such as BEM (3), or other unwanted minor components if required, prior to carrying out step c). Suitable organic solvents for this washing step are in general organic solvents which are immiscible in water 5 but miscible with the water miscible organic solvent used in step a). When the water miscible organic solvent in step a) is acetonitrile, suitable organic solvents for the washing step are ester, ether and hydrocarbon solvents known in the art. Examples of such suitable solvents are xylene (hydrocarbon solvent), methyl-t-butylether (MTBE) (ether solvent) and ethyl acetate (ester solvent). The toluene or other suitable organic solvent may conveniently be removed 10 from the process by phase separation. Any solvent remaining after phase separation may be removed in Step d). Preferably the solvent is toluene. In one embodiment, the aqueous alkali metal salt is an aqueous sodium salt. In this embodiment, in step b), the aqueous sodium salt solution is washed with a suitable organic solvent. In one aspect of this embodiment, the aqueous sodium salt solution is washed with 15 toluene, xylene, MTBE or ethyl acetate. In a further aspect of this embodiment, the aqueous sodium salt solution is washed with toluene or xylene. In a further aspect of this embodiment, the aqueous sodium salt solution is washed with toluene. In a further aspect of this embodiment, the aqueous sodium salt solution is washed with MTBE. In a further aspect of this embodiment, the aqueous sodium salt solution is washed with ethyl 20 acetate. In another embodiment, in step b), the aqueous sodium salt solution is not washed with a suitable organic solvent. In an alternative embodiment of this invention, the aqueous alkali metal hydroxide is potassium hydroxide. It will be appreciated that in this embodiment, the potassium salt 25 equivalent of the sodium salt (2) is formed as a result. In this embodiment, suitable temperatures, concentrations of potassium hydroxide and washing solvents are those described as suitable for sodium hydroxide hereinbefore. Step) 30 Adjustment of the aqueous solution to pH 6 - 11 is suitably carried out by addition of hydrochloric acid, for example 0.02 to 1M aqueous hydrochloric acid. In one embodiment, the solution is adjusted to pH 8-11. In another embodiment, the solution is adjusted to pH 9 11, for example about pH 9-10.5. Suitably, the solution is adjusted to about pH 9-10.5 using WO 2004/108691 PCT/GB2004/002373 -6 a0.M hydrochloric acid. More suitably, the solution is adjusted to about pH 10.5 using about 0.1M hydrochloric acid. Preferably the solution is adjusted to about pH9, suitably using 0.02M aqueous hydrochloric acid. Other inorganic acids known in the art may also be used, provided the calcium salt of the inorganic acid is water soluble so that it is not precipitated in 5 Step f). Step d) The water miscible organic solvent (and residual amounts of any organic solvent used as a wash in step b) above), may generally be removed by distillation, conveniently carried 10 out under vacuum. When the water miscible organic solvent is acetonitrile, the distillation is suitably carried out for example using a vacuum of <55 mBar, and a temperature of 45 oC. Conveniently, the vacuum is about 52 mBar and the temperature is about 33'C. It will be appreciated by those skilled in the art that water may be azeotropically removed with the 15 acetonitrile during the distillation and that it may therefore be desirable to add further water to the mixture during the distillation process. A suitable method for carrying out the distillation is provided in the accompanying non-limiting Example. StepeC) 20 Filtration of the mixture resulting from step d) removes any unreacted starting material or insoluble impurities which may have precipitated during the distillation process of step d). It will be appreciated that water may be used to wash the filter. Any filter known in the art to be suitable may be used. Conveniently at a manufacturing scale, a GaF filter may be used (for example, a GAF filter E6-1825, manufactured by "Haywood Industrial Products). 25 It will be appreciated that this filtration is not always necessary and may be omitted. Step f) Generally, the water soluble calcium salt is suitably any such salt whose counter-ion forms a water soluble salt with sodium, such that it is easily removed by washing the product 30 after isolation in step g). Suitable water soluble calcium salts include calcium chloride, calcium bromide and calcium acetate. More suitably, calcium chloride or calcium bromide is used. In one embodiment, the water soluble calcium salt is calcium chloride.

WO 2004/108691 PCT/GB2004/002373 -7 In this embodiment, calcium chloride is conveniently provided as its dihydrate form and is suitably added to the filtrate as an aqueous solution. A slight excess of calcium chloride may be used, for example 0.6 molar equivalents compared to the Agent. The calcium chloride is suitably added as a 0.1 g/ml aqueous solution. The temperature of the reaction 5 mixture is suitably maintained at 32-43oC, more suitably at approximately 40 0 C, during the addition process. The rate of addition of calcium chloride may be adjusted such that the temperature of the reaction mixture is so maintained. Suitably the calcium chloride is added over 15-30 minutes. The mixture may be maintained at the addition temperature for a period (herein referred to as the 'hold time') before isolation of the calcium salt. In one embodiment, 10 the hold time is at least 10 minutes. In another embodiment the hold time is at least 20 minutes. In a further embodiment the hold time is at least 30 minutes. Step g) Isolation of the calcium salt may conveniently be carried out by filtration, 15 conveniently at about 20 0 C (herein referred to as the "filtration temperature"). The mixture may be maintained at the filtration temperature for a period before filtration is carried out, for example for 10 to 20 minutes, conveniently for 15 minutes. It will be appreciated that water may be used to wash the filtrate. 20 According to the present invention there is provided an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a) to g): a) reaction of tert-butyl (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2 25 [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl } (4R,6S)-2,2-dimethyl[ 1,3] dioxan-4 yl)acetate (BEM) in acetonitrile with aqueous hydrochloric acid at an elevated temperature; b) reaction of the resulting solution with aqueous sodium hydroxide; c) adjustment of the pH of the resulting solution to between pH6 and pHi 1; d) removal of acetonitrile; 30 e) filtration of the resulting mixture; f) addition of calcium chloride to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6 isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6 enoic acid calcium salt; and WO 2004/108691 PCT/GB2004/002373 -8 g) isolation of the product of step f). In a further aspect of the invention there is provided an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 5 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a), b) c), d), f) and g) as described hereinbefore. According to the present invention is provided an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5 10 yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): a') reaction of a (1-6C)alkyl ester of (E)-(6- {2-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl I (4R,6S)-2,2-dimethyl[ 1,3]dioxan-4 yl)acetic acid in acetonitrile with aqueous hydrochloric acid at an elevated temperature; b) reaction of the resulting solution with aqueous sodium hydroxide; 15 c) adjustment of the pH of the resulting solution to between pH6 and pHl 1; d) removal of acetonitrile; e) filtration of the resulting mixture; f) addition of calcium chloride to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6 isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3 ,5-dihydroxyhept-6 20 enoic acid calcium salt; and g) isolation of the product of step f). In a further aspect of the invention is provided an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5 yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a'), b) c), 25 d), f) and g) as described hereinbefore. In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid 30 calcium salt, which comprises the steps a) to g): a) reaction of tert-butyl (E)-(6- { 2-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl I (4R,6S)-2,2-dimethyl[ 1,3]dioxan-4 yl)acetate (BEM) in acetonitrile with aqueous hydrochloric acid at 35-40 0

C;

WO 2004/108691 PCT/GB2004/002373 "9 b) reaction of the resulting solution with IM sodium hydroxide at ambient temperature and optionally washing the resulting aqueous sodium salt solution with a suitable organic solvent; c) adjustment of the pH of the resulting solution to about pH9 by addition of <0.05M 5 aqueous hydrochloric acid; d) removal of acetonitrile by distillation at 50-55mBar and 30-35 0 C; e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5 10 yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43 0 C; and g) isolation of the product of step f) by filtration at about 20 0 C. In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid 15 calcium salt, which comprises the steps a') to g): a') reaction of a (1-6C)alkyl ester of (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-y1]vinyl I (4R,6S)-2,2-dimethyl [ 1,3]dioxan-4 yl)acetic acid in acetonitrile with aqueous hydrochloric acid at 35-40°C; b) reaction of the resulting solution with 1M sodium hydroxide at ambient temperature 20 and optionally washing the resulting aqueous sodium salt solution with a suitable organic solvent; c) adjustment of the pH of the resulting solution to about pH9 by addition of <0.05M aqueous hydrochloric acid; d) removal of acetonitrile by distillation at 50-55mBar and 30-35 0 C; 25 e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5 yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43'C; and g) isolation of the product of step f) by filtration at about 20'C. 30 In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a) to g): WO 2004/108691 PCT/GB2004/002373 -10 a) reaction of tert-butyl (E)-(6-{ 2-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl } (4R,6S)-2,2-dimethyl[1,3]dioxan-4 yl)acetate (BEM) in acetonitrile with aqueous hydrochloric acid at 35-40'C; b) reaction of the resulting solution with IM sodium hydroxide at ambient temperature 5 and optionally washing the resulting aqueous sodium salt solution with a suitable organic solvent; c) adjustment of the pH of the resulting solution to about pH 9-10.5 using 50.1M aqueous hydrochloric acid d) removal of acetonitrile by distillation at 50-55mBar and 30-35 0 C; 10 e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5 yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43 0 C; and g) isolation of the product of step f) by filtration at about 20 0 C. 15 In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): a') reaction of a (1-6C)alkyl ester of (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2 20 [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl } (4R,6S)-2,2-dimethyl[ 1,3]dioxan-4 yl)acetic acid in acetonitrile with aqueous hydrochloric acid at 35-40 0 C; b) reaction of the resulting solution with 1M sodium hydroxide at ambient temperature and optionally washing the resulting aqueous sodium salt solution with a suitable organic solvent; 25 c) adjustment of the pH of the resulting solution to about pH 9-10.5 using 50.1M aqueous hydrochloric acid d) removal of acetonitrile by distillation at 50-55mBar and 30-35 0 C; e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to 30 form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5 yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43 0 C; and g) isolation of the product of step f) by filtration at about 20 0

C.

WO 2004/108691 PCT/GB2004/002373 -11 In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): 5 a') reaction of a (1-6C)alkyl ester of (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl} (4R,6S)-2,2-dimethyl[1,3]dioxan-4 yl)acetic acid in acetonitrile with aqueous hydrochloric acid at 35-40 0 C; b) reaction of the resulting solution with 1M sodium hydroxide at ambient temperature and optionally washing the resulting aqueous sodium salt solution with a suitable 10 hydrocarbon, ester or ether solvent; c) adjustment of the pH of the resulting solution to about pH 9-10.5 using 50.1M aqueous hydrochloric acid d) removal of acetonitrile by distillation at 50-55mBar and 30-35 0 C; e) filtration of the resulting mixture; 15 f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5 yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43oC; and g) isolation of the product of step f) by filtration at about 20 0 C. In a further embodiment, the present invention provides an improved process for the 20 formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): a') reaction of a (1-6C)alkyl ester of (E)-(6-{ 2-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl } (4R,6S)-2,2-dimethyl[1,3]dioxan-4 25 yl)acetic acid in acetonitrile with aqueous hydrochloric acid at 35-40oC; b) reaction of the resulting solution with IM sodium hydroxide at ambient temperature and optionally washing the resulting aqueous sodium salt solution with toluene, xylene, MTBE or ethylacetate; c) adjustment of the pH of the resulting solution to about pH 9-10.5 using 50. 1M 30 aqueous hydrochloric acid d) removal of acetonitrile by distillation at 50-55mBar and 30-35oC; e) filtration of the resulting mixture; WO 2004/108691 PCT/GB2004/002373 -12 f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)aminopyrimidin-5 yl]J(3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43 0 C; and g) isolation of the product of step f) by filtration at about 20'C. 5 In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): a') reaction of a (1-6C)alkyl ester of (E)-(6- {2-[4-(4-fluorophenyl)-6-isopropyl-2 10 [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl } (4R,6S)-2,2-dimethyl[ 1,3]dioxan-4 yl)acetic acid in acetonitrile with aqueous hydrochloric acid at 35-40'C; b) reaction of the resulting solution with IM sodium hydroxide at ambient temperature and optionally washing the resulting aqueous sodium salt solution with toluene; c) adjustment of the pH of the resulting solution to about pH 9-10.5 using <0.1M 15 aqueous hydrochloric acid d) removal of acetonitrile by distillation at 50-55mBar and 30-35 0 C; e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5 20 yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43 0 C; and g) isolation of the product of step f) by filtration at about 20 0 C. In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 25 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): a') reaction of a (1-6C)alkyl ester of (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl } (4R,6S)-2,2-dimethyl[ 1,3]dioxan-4 yl)acetic acid in acetonitrile with aqueous hydrochloric acid at 35-40 0 C; 30 b) reaction of the resulting solution with 1M sodium hydroxide at ambient temperature and washing the resulting aqueous sodium salt solution with a suitable hydrocarbon, ester or ether solvent; WO 2004/108691 PCT/GB2004/002373 -13 c) adjustment of the pH of the resulting solution to about pH 9-10.5 using 0. 1M aqueous hydrochloric acid d) removal of acetonitrile by distillation at 50-55mBar and 30-35°C; e) filtration of the resulting mixture; 5 f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5 yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43 0 C; and g) isolation of the product of step f) by filtration at about 20'C. In a further embodiment, the present invention provides an improved process for the 10 formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, which comprises the steps a') to g): a') reaction of a (1-6C)alkyl ester of (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl} (4R,6S)-2,2-dimethyl[ 1,3]dioxan-4 15 yl)acetic acid in acetonitrile with aqueous hydrochloric acid at 35-40'C; b) reaction of the resulting solution with 1M sodium hydroxide at ambient temperature and washing the resulting aqueous sodium salt solution with toluene, xylene, MTBE or ethylacetate; c) adjustment of the pH of the resulting solution to about pH 9-10.5 using 50.1M 20 aqueous hydrochloric acid d) removal of acetonitrile by distillation at 50-55mBar and 30-35'C; e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5 25 yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43 0 C; and g) isolation of the product of step f) by filtration at about 20'C. In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid 30 calcium salt, which comprises the steps a') to g): a') reaction of a (1-6C)alkyl ester of (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl } (4R,6S)-2,2-dimethyl[ 1,3]dioxan-4 yl)acetic acid in acetonitrile with aqueous hydrochloric acid at 35-40 0

C;

WO 2004/108691 PCT/GB2004/002373 -14 b) reaction of the resulting solution with 1M sodium hydroxide at ambient temperature and washing the resulting aqueous sodium salt solution with toluene; c) adjustment of the pH of the resulting solution to about pH 9-10.5 using 50.1M aqueous hydrochloric acid 5 d) removal of acetonitrile by distillation at 50-55mBar and 30-35 0 C; e) filtration of the resulting mixture; f) addition of an aqueous solution of calcium chloride dihydrate to the filtrate so as to form (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5 yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt, at 32-43 0 C; and 10 g) isolation of the product of step f) by filtration at about 20 0 C. In a further embodiment, the present invention provides an improved process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid 15 calcium salt, which comprises the steps a') to g) as described in any aspect or embodiment hereinbefore or hereinafter, wherein, in step b), potassium hydroxide is used instead of sodium hydroxide. The process of the invention generally results in improved overall percentage yield (starting from BEM or other (1-6C)alkyl ester) and a reduced number of steps in comparison 20 with the processes known in the art. It will be appreciated that a higher percentage yield may provide a significant cost benefit when manufacture is taking place on a commercial scale. The reduced number of steps in the process of the invention results in fewer operational processes during the manufacture, which may translate into a more robust process. The reduced number of steps in the process of the invention involves reduced handling of material, 25 which may result in less opportunity for degradation or contamination of the product. Also, certain chemical reagents are no longer required and the total amount of waste and/or effluent is reduced, providing an environmental benefit. A further aspect of the invention provides the compound (E)-7-[4-(4-fluorophenyl)-6 isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3 ,5-dihydroxyhept-6 30 enoic acid calcium salt made by the process steps a) to g) as hereinbefore described. A further aspect of the invention provides the compound (E)-7-[4-(4-fluorophenyl)-6 isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6- WO 2004/108691 PCT/GB2004/002373 -15 enoic acid calcium salt made by the process steps a') to g) as described in any aspect or embodiment hereinbefore. Therefore a further aspect of the invention provides a product obtainable by the 5 process of the present invention. Another aspect of the invention provides a product obtained by the process of the present invention. It will be appreciated that the process of the current invention could be applied to make alternative salts of the Agent, such as the magnesium salt by use of a suitable 10 magnesium salt in step f), such as magnesium chloride. Such a salt thus obtained could be converted by processes known in the art into the calcium salt (1). Thus in another aspect of the invention, is provided a process for making the magnesium salt of the Agent, comprising the steps a) to g) as hereinbefore described wherein, in step f) a water soluble magnesium salt (such as magnesium chloride) is added instead of a water soluble calcium salt (such as 15 calcium chloride). The invention is further illustrated by the following examples. Example 1 BEM (20.0g) was dissolved in acetonitrile (140ml) at 40 0 C, then cooled to 35°C before 20 gradual addition of hydrochloric acid (0.02M, 35ml) at 35°C. The resulting solution was stirred at 35'C until the reaction was complete then cooled to 25 0 C. Sodium hydroxide (1.0M, 38ml) was added at 25 0 C and the resulting mixture stirred at this temperature until the reaction was complete. Aqueous hydrochloric acid (LM) was added to adjust the pH of the solution to pH9. The solution was distilled under reduced pressure (52mBar, <40 0 C) until 25 approximately 100ml of acetonitrile/water had been removed. Water (100ml) was added and distillation continued until a further 100ml of acetonitrile/water had been removed. The resulting mixture was filtered through a filter pad, the filter washed with water (30mi) and the filtrates heated to 40 0 C before addition of a solution of calcium chloride dihydrate (3.07g) in water (29.5ml) over 20min, maintaining the reaction mixture at 38-41 0 C. 30 The reaction mixture was stirred for a further 15min at 40'C, then cooled to 20'C and stirred at this temperature for a further 15min. The resulting suspension was filtered, washed with water (3 x 50ml) and dried to give (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- WO 2004/108691 PCT/GB2004/002373 -16 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt (15.8g, 84% yield). Example 2 5 The synthesis of analogues of BEM is illustrated below for the iso-propyl analogue. Other analogues can be made by similar procedures. iso-Propyl (E)-(6-{2-r[4-(4-fluorophenyl)-6-isopropvl-2-[methyl(methylsulfonvyl)amniino] pyrimniidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[1,3]dioxan-4-vl)acetate 10 Sodium bis(trimethylsilyl)amide (80.47 mL, 1.0M in THF) was added dropwise to a cooled solution of diphenyl [4-(4-fluoropheny)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-ylmethyl] phosphine oxide (40.43 g, 75 mmol) in THF (477.1 mL) at -65 0 C over 30 minutes, maintaining the temperature at -65 0 C. Isopropyl- 2-[(4R,6S)-6-formyl-2,2 dimethyl-1,3-dioxan-4-yl}acetate in toluene (21.68 g) was added dropwise to the solution 15 over 35 minutes, maintaining the temperature at -65 0 C. The contents of the vessel were kept at -65 0 C for 15 minutes, then allowed to warm evenly to 10 0 C over 80 minutes. Water (40.4 mL) followed by acetic acid (6.87 g, 114 mmol) were added to give a two phase light yellow solution. The batch was then distilled at atmospheric pressure to remove - 485 mL of distillates. This solution was washed sequentially with water (84 mL), 7.0% w/w sodium 20 bicarbonate (92.6 g), 1.8% w/w sodium bicarbonate (91.1 g) and water (63.5 mL). The resulting organic phase was distilled under vacuum at 270 mbar to leave - 95 mL of solution in the distillation flask (removing ~ 229mL of distillates). Methanol (202 mL) at 50 0 C was charged to the flask and the solution distilled at atmospheric pressure, removing ~ 134 mL of distillates. A further portion of methanol (229 mL) at 50 0 C was added to the solution and the 25 batch cooled to 40 0 C over 30 minutes. The batch was cooled to 25 0 C over 30 minutes, 0-5 0 C over 30 minutes, then chilled to -8 0 C over 20 minutes and kept at this temperature for 30 minutes. The solid was collected by vacuum filtration, washed with 2 portions of cooled ( 8 0 C) methanol (2 x 80.6 mL) then dried in a vacuum oven at 50 0 C, 200 mbar, yield = 28.9 g (68.3%). 30 1 H NMR 8: 1.15 (q, 1H) 1.24 (dd, 6H) 1.27 (dd, 6H) 1.40 (s, 3H) 1.49 (s, 3H) 1.55 (dt, 1H) 2.34 (dd, 1H) 2.50 (dd, 1H) 3.38 (spt, 1H) 3.51 (s, 3H) 3.57 (s, 3H) 4.32 (m, 1H) 4.43 (m, 1H) 5.04 (spt, 1H11) 5.47 (dd, 1H) 6.52 (d, 1H) 7.08 (t, 2H) 7.65 (dd, 2H) WO 2004/108691 PCT/GB2004/002373 -17 Isopropyl- 2-[(4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl } acetate Chlorine gas (2469.6 mL, 118 mmol) was charged to toluene (373.3 mL, 16 rel vol) at -60 0 C. Dimethyl sulphide (11.67 mL, 121 mmol) was then added dropwise to the cooled solution over 30 minutes, keeping the contents at -60 0 C. After 30 minutes at this temperature, iso 5 propyl 2-[(4R,6S)-6-hydroxymethyl-2,2-dimethyl- 1,3-dioxan-4-yl}acetate (24.56 g, 95 mmol) in toluene (46.7 mL) was added dropwise to the vessel over 30 minutes, maintaining the internal temperature at -60 0 C. The reaction mixture was agitated at -60 0 C for 30 minutes followed by the dropwise addition of triethylamine (26.36 g, 261 mmol) over 30 minutes, allowing the internal temperature to rise to -50 0 C. The reaction mixture was then allowed to 10 warm to 25 0 C evenly over 75 minutes. The resulting slurry was stirred at 25 0 C for 30 minutes, then water (77 mL) was added and the mixture agitated for 30 minutes. The aqueous layer was separated and the pH checked (pH should be between 7.5 and 8.5). The resulting organic portion was washed with water (23.3 mL) and the organic portion separated for vacuum distillation at 150 mbar. Distillation was continued until ~350 mL of toluene had been 15 removed. Toluene (350 mL) was added to the flask and the vacuum distillation repeated at 150 mbar to remove -350 mL of toluene. The resulting solution was transferred to a flask containing activated 4 angstrom molecular sieves and left at ambient temperature overnight. This solution was used directly for the coupling stage. 20 Iso-propyl 2-[(4R,6S)-6-hydroxymethyl-2,2-dimethyl-1,3-dioxan-4-yl I acetate This compound may be made using the procedures described in EPO319847. Analogues with different ester groups R may be made by a similar method. Diphenyl [4-(4-fluoropheny)-6-isopropyl-2-[methyl(methylsulfonyl)aminolpyrimidin-5 25 ylmethyl] phosphine oxide This compound can be made as described in Patent Application WO00/49014 Example 3: Procedure using wash in step b) BEM (20.0g) was dissolved in acetonitrile (140ml) at 40 0 C, then cooled to 35 0 C before 30 gradual addition of hydrochloric acid (0.02M, 35ml) at 35 0 C. The resulting solution was stirred at 35 0 C until the reaction was complete then cooled to 25oC. Further acetonitrile (8 ml) was added before sodium hydroxide (1.0M, 38ml) was added at 25 0 C and the resulting mixture stirred at this temperature until the reaction was complete. Aqueous hydrochloric WO 2004/108691 PCT/GB2004/002373 -18 acid (0.1 M) was added to adjust the pH of the solution to approximately pH10.5. Water was added so that the combined volume of water and hydrochloric acid (0.1M) (from the previous pH adjustment step) added was 100ml. Toluene (125 ml) was then added and the mixture stirred at 40 0 C for 30 minutes before it was allowed to settle for 1 hour at 40 0 C. The aqueous 5 phase was then separated from the organic phase at 40'C. The aqueous phase was distilled under reduced pressure (53mBar, <40'C) until the volume was reduced to135 ml. The resulting aqueous solution was filtered through a filter pad and the filter washed with water and combined with the aqueous reaction solution, such that the total volume of the resulting aqueous solution was 170 ml. This solution was heated to 40'C before addition of a solution 10 of calcium chloride di-hydrate (3.05g) in water (29.5ml) over 20min, maintaining the reaction mixture at 38-41oC. The reaction mixture was stirred for a further 15 min at 40 0 C, then cooled to 20 0 C and stirred at this temperature for a further 15min. The resulting suspension was filtered, washed with water (3 x 53ml) and dried to give (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 15 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt (14.7g @ 100% strength, 85% yield). 'H NMR 8: 1.21 (d+d, 6H) 1.32 (dt, 1H) 1.51 (dt, 1H) 2.00 (dd, 1H) 2.14 (dd, 1H) 3.42 (spt, 1H)* 3.45 (s, 3H) 3.54 (s, 3H) 3.77 (m, 1H) 4.21 (q, 1H) 5.53 (dd, 1H) 6.51 (dd, 1H) 7.27 (t, 2H) 7.71 (dd, 2H) 20 [The 1H NMR was carried out as a 3% w/v solution in d 6 DMSO (where d 5 DMSO=2.515)]. *partially obscured 25

Claims

1. A process for the formation of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid 5 calcium salt, which comprises the steps a) to g): a) reaction of a (1-6C)alkyl ester of (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl } (4R,6S)-2,2-dimethyl[ 1,3]dioxan-4 yl)acetic acid in a water miscible organic solvent with aqueous acid at an elevated temperature; 10 b) reaction of the resulting solution with an aqueous alkali metal hydroxide and optionally washing the resulting aqueous alkali metal salt solution with a suitable organic solvent; c) adjustment of the pH of the resulting solution to between pH6 and pHil 1; d) removal of the water miscible organic solvent; 15 e) optional filtration of the resulting mixture; f) addition of a water soluble calcium salt to the filtrate so as to form (E)-7-[4-(4 fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5 dihydroxyhept-6-enoic acid calcium salt; and g) isolation of the product of step f). 20

2. A process as claimed in Claim 1 wherein the water miscible organic solvent is acetonitrile.

3. A process as claimed in Claim 1 or Claim 2 wherein in step a) the aqueous acid is 25 hydrochloric acid.

4 A process as claimed in any one of the preceding claims wherein step b) comprises: reaction of the resulting solution with aqueous sodium hydroxide and washing the resulting aqueous sodium salt solution with a suitable hydrocarbon, ester or ether solvent. 30

5. A process as claimed in any one of the preceding claims wherein the aqueous sodium salt solution is washed with toluene, xylene, MTBE or ethyl acetate. WO 2004/108691 PCT/GB2004/002373 -20

6. A process as claimed in Claim 5 wherein the aqueous sodium salt solution is washed with toluene.

7. A process as claimed in any one of the preceding claims wherein the (1-6C)alkyl ester 5 is the tert-butyl ester.

8. A process as claimed in any one of the preceding claims wherein step a) is carried out at 35-400C. 10

9. A process as claimed in any one of the preceding claims wherein step b) is carried out at ambient temperature.

10. A process as claimed in Claim 1 wherein in step b), the aqueous alkali metal hydroxide is potassium hydroxide. 15

11. A process as claimed in any one of the preceding claims wherein step c) comprises adjustment of the pH of the solution to about pH9-10.5 by addition of aqueous hydrochloric acid. 20

12 A process as claimed in any one of the preceding claims wherein step d) is carried out at a pressure of <55mBar and a temerature of _45 0 C.

13. A process as claimed in any one of the preceding claims wherein in step f) the water soluble calcium salt is calcium chloride. 25

14. A process as claimed in any one of the preceding claims wherein in step f) the calcium salt is added at 32-43 0 C.

15. The compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 30 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt made by the process steps a) to g) as claimed in Claim 1. WO 2004/108691 PCT/GB2004/002373 -21

16. The compound (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2 [methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt made by the process steps a) to g) as claimed in Claim 7. 5